143 related articles for article (PubMed ID: 10945311)
1. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration.
Seidegård J
Clin Pharmacol Ther; 2000 Jul; 68(1):13-7. PubMed ID: 10945311
[TBL] [Abstract][Full Text] [Related]
2. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
3. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
4. Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole.
Seidegård J; Nyberg L; Borgå O
Eur J Pharm Sci; 2008 Nov; 35(4):264-70. PubMed ID: 18706998
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.
Swart PJ; Krauwinkel WJ; Smulders RA; Smith NN
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):33-6. PubMed ID: 16867168
[TBL] [Abstract][Full Text] [Related]
6. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans.
Herman BD; Fleishaker JC; Brown MT
Clin Pharmacol Ther; 1999 Oct; 66(4):374-9. PubMed ID: 10546921
[TBL] [Abstract][Full Text] [Related]
7. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
[TBL] [Abstract][Full Text] [Related]
8. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis.
Dilger K; Denk A; Heeg MH; Beuers U
Hepatology; 2005 Mar; 41(3):595-602. PubMed ID: 15726657
[TBL] [Abstract][Full Text] [Related]
9. Dietary salt increases first-pass elimination of oral quinidine.
Darbar D; Dell'Orto S; Mörike K; Wilkinson GR; Roden DM
Clin Pharmacol Ther; 1997 Mar; 61(3):292-300. PubMed ID: 9084454
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: an open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers.
Piñeyro-López A; Pineyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez Silva M; Wacksman N; Lujàn Rangel R; de Lago A; Trejo D; Gonzàlez-de la Parra M; Namur S
Clin Ther; 2006 Jan; 28(1):110-5. PubMed ID: 16490584
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
[TBL] [Abstract][Full Text] [Related]
12. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats.
Zhang Y; Hsieh Y; Izumi T; Lin ET; Benet LZ
J Pharmacol Exp Ther; 1998 Oct; 287(1):246-52. PubMed ID: 9765344
[TBL] [Abstract][Full Text] [Related]
13. Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: a double drug interaction study.
Dilger K; Fux R; Röck D; Mörike K; Gleiter CH
J Clin Pharmacol; 2007 Dec; 47(12):1532-9. PubMed ID: 18048573
[TBL] [Abstract][Full Text] [Related]
14. Alprazolam-ritonavir interaction: implications for product labeling.
Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
[TBL] [Abstract][Full Text] [Related]
15. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.
Zhao P; Ragueneau-Majlessi I; Zhang L; Strong JM; Reynolds KS; Levy RH; Thummel KE; Huang SM
J Clin Pharmacol; 2009 Mar; 49(3):351-9. PubMed ID: 19246732
[TBL] [Abstract][Full Text] [Related]
16. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Ward KW; Stelman GJ; Morgan JA; Zeigler KS; Azzarano LM; Kehler JR; McSurdy-Freed JE; Proksch JW; Smith BR
Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938
[TBL] [Abstract][Full Text] [Related]
17. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
18. The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study.
Oo C; Chen YC
J Clin Pharmacol; 2009 Mar; 49(3):368-9; author reply 370. PubMed ID: 19246734
[No Abstract] [Full Text] [Related]
19. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
Varis T; Kivistö KT; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
